Companies › XingImaging
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [¹⁸F]MK-0947 alpha-synuclein (ASYN) PET imaging agent | SNCA | Phase 1 | Parkinsons Disease (PD) | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07880379 | [¹⁸F]MK-0947 | Phase 1 | Parkinsons Disease (PD) | Neurology | Sep 2027 |
Teva Branded Pharmaceutical Products R&D AC Immune Regeneron Pharmaceuticals Roche
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.